CN102018805A - Drug for treating relapsable vulvovaginal candidiasis - Google Patents
Drug for treating relapsable vulvovaginal candidiasis Download PDFInfo
- Publication number
- CN102018805A CN102018805A CN2010105939963A CN201010593996A CN102018805A CN 102018805 A CN102018805 A CN 102018805A CN 2010105939963 A CN2010105939963 A CN 2010105939963A CN 201010593996 A CN201010593996 A CN 201010593996A CN 102018805 A CN102018805 A CN 102018805A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- drug
- treatment
- lactein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a drug for treating relapsable vulvovaginal candidiasis, which is prepared by mixing 30-80ml of fluconazole with the following medicinal components in parts by weight: 2-4 parts of ketoconazole or 2-4 parts of itraconazole, 2-4 parts of metronidazole, 4-6 parts of lactein, 10-30 parts of calcined borax, 10-30 parts of golden cypress, 10-30 parts of coptis, 10-30 parts of vietnamese sophora root, 10-30 parts of borneol and 10-30 parts of mint. In the invention, western medicines and natural traditional Chinese medicines which are sensitive to the relapsable vulvovaginal candidiasis are used as raw materials for treatment, and the drug disclosed by the invention has no toxicity and side effect, and is safe and durable. The drug disclosed by the invention has the advantages of remarkable curative effect, high cure rate, low relapse rate, short course and no drug dependence, can treat both principle and secondary aspect of disease, and is economical and efficient; and the used instrument is simple and low in toxicity and side effect.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of the recurrent VVC.
Background technology
The vulvovaginal candida mycoderma is read the bacterium disease, and (vulvovaginal candidiasis VVC) also claims vulvovaginal candidiasis, is common pudendum, colpitis.10% non-gravid woman is arranged approximately, have candidiasis parasitic and asymptomatic in gravid woman's vagina of 30%.70% women infected once in life at least.The white candida mycoderma is main pathogens (80%～90%).Many women because of leucorrhoea grow in quantity, abnormal flavour, vulvovaginal pruritus causalgia unbearably, especially VVC passability life etc. directly with the indirect mode propagation, cause cross infection between men and women's property, this disease is owing to the body defensive enginery reduces, treatment is not thorough, cross infection makes the disease protracted course of disease, make women's mood irritated or depressed, agonizing, seek medical advice everywhere, influence work, social activity and sexual life, having become influences household economy, fertility, harmonious and stable domestic problem; One seriously influences the stable public health problem of Chinese society especially.Still there is not at present satisfied Therapeutic Method.The western medicine method has weak point: 1. effect is undesirable, 2. is easy to recurrence, protracted course of disease; 3. can't thoroughly effect a radical cure 4. dysbacteriosiss.
Summary of the invention
The purpose of this invention is to provide a kind of evident in efficacy, relapse rate is low, toxic and side effects is light, the medicine of the treatment recurrent VVC of no drug dependence.
Medicine in first kind of embodiment raw material of medicine of the present invention is formed and the weight portion proportioning is:
10～30 parts of 2～4 parts of ketoconazoles, 2～4 parts of metronidazoles, 4 parts～6 parts of lactein, 10～30 parts of Borax(calcined), 10～30 parts of Cortex Phellodendris, 10～30 parts of Rhizoma Coptidis, 10～30 parts of Radix Sophorae Tonkinensiss, 10～30 parts of Borneolum Syntheticums and Herba Menthaes, said medicine porphyrize and fluconazol 30～80ml mix.
Medicine in the said medicine raw material is formed and the weight portion proportion optimization is:
20 parts of 4 parts of ketoconazoles, 2 parts of metronidazoles, 4 parts of lactein, 20 parts of Borax(calcined), 20 parts of Cortex Phellodendris, 20 parts of Rhizoma Coptidis, 20 parts of Radix Sophorae Tonkinensiss, 20 parts of Borneolum Syntheticums and Herba Menthaes, said medicine porphyrize and fluconazol 50ml mix.
Medicine in second kind of embodiment raw material of medicine of the present invention is formed and the weight portion proportioning is:
2 parts～4 parts of itraconazoles, 2～4 parts of metronidazoles, 4 parts～6 parts of lactein, 10～30 parts of 10～30 parts of Borax(calcined), 10～30 parts of Cortex Phellodendris, 10～30 parts of Rhizoma Coptidis, 10～30 parts of Radix Sophorae Tonkinensiss, 10～30 parts of Borneolum Syntheticums and Herba Menthaes, said medicine porphyrize and fluconazol 30～80ml mix.
Medicine in the said medicine raw material is formed and the weight portion proportion optimization is:
20 parts of 1.2 parts of itraconazoles, 2 parts of metronidazoles, 4 parts of lactein, 20 parts of Borax(calcined), 20 parts of Cortex Phellodendris, 20 parts of Rhizoma Coptidis, 20 parts of Radix Sophorae Tonkinensiss, 20 parts of Borneolum Syntheticums and Herba Menthaes, said medicine porphyrize and fluconazol 50ml mix.
Medicine of the present invention is unguentum or pill.
Solution of the present invention is based on Chinese and western medicine to pathogenetic understanding of recurrent VVC and Therapeutic Principle.Doctor trained in Western medicine is thought VVC through treatment, and clinical symptoms and sign disappear, and occur symptom again after the mycology inspection feminine gender, and mycology is checked positive, and in 1 year outbreak 4 times or more than, obstinate, antifungal therapy are its Therapeutic Principle.VVC belongs to Chinese medicine " pudendal pruritus ", " leukorrhagia " category, and the cause of disease is a lot of, and pathogeny is many and insufficiency of the spleen, and damp invasion of lower energizer is relevant, and adopting spleen invigorating, dehumidifying, killing parasites for relieving itching is the Therapeutic Principle, treating both the principal and secondary aspects of a disease.
Prescription medicine spreads upon pudendum and vagina, and fluconazol liquid, ketoconazole and itraconazole can evenly be adsorbed on the vagina pleat that struts and around the pudendum, reduce inflammation rapidly.Metronidazole can be killed vagina anaerobe and other assorted bacterium, and lactein can promote the growth of vagina lactobacillus, keeps the vaginal microbial flora balance, has reduced the recurrence of disease.Cortex Phellodendri, Rhizoma Coptidis, Radix Sophorae Tonkinensis use in prescription as adjuvant drug as ministerial drug, watermelon crystal, Borneolum Syntheticum, Mentholum etc., have heat-clearing and toxic substances removing, anti-inflammation detumescence, increase the absorbability of soaking into of medicine, dispel abnormal flavour of leucorrhea, increase the effect of patient Xin Liang comfort; Use lactein to promote the growth of vagina lactobacillus,, kept the vaginal microbial flora balance, reduced relapse rate for the growth of normal flora provides control environment.
The clinical efficacy situation statistics of 354 routine recurrent VVCs of prescription medicine treatment of the present invention is as follows:
1. case is selected
The patient of recurrent VVC (get rid of gestation and age of sucking patient) 354 examples, the age is at 20～60 years old, average 34.1 years old, the course of disease 1～12 year, average 2.1 years, meet the diagnostic criteria of recurrent VVC, give the composition of medicine treatment.
Therapeutic Method
Treat 1 time in the 1st, the 2 every days course of treatment, treat continuously 10 times.
Patient's emptying bladder is got lithotomy position, and the rearmounted placement of sterilization pudendum vaginal speculum: 4%NaHCO3 solution 200ml carries out the vulvovaginal flushing, and vulvovaginal is smeared first prescription medicine then, uses radiation of visible light vulvovaginal 20 minutes; Treat the taking-up vaginal speculum that finishes.
In the 3rd course of treatment, treat 1 time every day with second prescription, to treat continuously 10 times, method is the same.
Curative effect judging standard
Cure: transference cure, the vaginal mucosa color is normal, the normal and free from extraneous odour of leucorrhea color.Continuously March the microscopy feminine gender.
Effectively: symptom obviously alleviates or disappears, the leucorrhea free from extraneous odour.March, microscopy had the positive continuously.
Invalid: symptom and sign alleviates slightly or does not have change, and the microscopy positive is invalid.
Recurrence: RVVC is through treatment, and clinical symptoms and sign disappear, and fungus is checked all negative back symptom reproduction of continuous 3 cycles, and fungus is checked and is positive, and then belongs to recurrence.
The curative effect statistics
Find out that from last table the total effective rate that the present invention treats the recurrent VVC is
?99.4%。
5. the vagina cleanness degree situation is added up
| ? | Vagina cleanness degree (I) | Vagina cleanness degree (II) | Vagina cleanness degree (more than the II) |
| Treated the 4th day | 25.5% | 67.3% | 7.2% |
| Drug withdrawal the 6th day | 53.5% | 41.7% | 4.8% |
Find out that from last table the present invention treats the recurrent VVC can obviously improve vagina cleanness degree, effective percentage reaches more than 93%.
The specific embodiment
The following examples can make those skilled in the art more fully understand the present invention, but do not limit the present invention in any way.
Embodiment 1.
Prepare medicine and treat by following weight proportion:
First prescription: ketoconazole 4g, metronidazole 4g, lactein 6g, Borax (forging) 30g, Cortex Phellodendri 30g, Rhizoma Coptidis 30g, Radix Sophorae Tonkinensis 30g, Borneolum Syntheticum 30g, Herba Menthae 30g porphyrize mix with fluconazol 80ml.Be distributed into 10 bottles.
Second prescription: itraconazole 4g, metronidazole 4g, lactein 6g, Borax (forging) 30g, Cortex Phellodendri 30g, Rhizoma Coptidis 30g, Radix Sophorae Tonkinensis 30g, Borneolum Syntheticum 30g, Herba Menthae 30g porphyrize mix with fluconazol 80ml.Be distributed into 10 bottles.
Treat 1 time in the 1st, the 2 every days course of treatment, treat continuously 10 times.Patient's emptying bladder is got lithotomy position, and the rearmounted placement of sterilization pudendum vaginal speculum: the NaHCO3 solution 200ml with concentration 4% carries out the vulvovaginal flushing, and vulvovaginal is smeared first prescription medicine then, uses radiation of visible light vulvovaginal 20 minutes; Treat the taking-up vaginal speculum that finishes.In the 3rd course of treatment, to treat 3-7 time continuously with second prescription, method is the same.Be after treatment the 3rd course of treatment.
Embodiment 2.
Prepare medicine and treat by following weight proportion:
First prescription: ketoconazole 2g, metronidazole 2g, lactein 4g, Borax (forging) 10g, Cortex Phellodendri 10g, Rhizoma Coptidis 10g, Radix Sophorae Tonkinensis 10g, Borneolum Syntheticum 10g, Herba Menthae 10g porphyrize mix with fluconazol 30ml.Be distributed into 10 bottles.
Second prescription: itraconazole 2g, metronidazole 2, lactein 4g, Borax (forging) 10g, Cortex Phellodendri 10g, Rhizoma Coptidis 10g, Radix Sophorae Tonkinensis 10g, Borneolum Syntheticum 10g, Herba Menthae 10g porphyrize mix with fluconazol 30.Be distributed into 10 bottles.
Treat 1 time in the 1st, the 2 every days course of treatment, treat continuously 10 times.Patient's emptying bladder is got lithotomy position, and the rearmounted placement of sterilization pudendum vaginal speculum: the NaHCO3 solution 200ml with concentration 4% carries out the vulvovaginal flushing, and vulvovaginal is smeared first prescription medicine then, uses radiation of visible light vulvovaginal 20 minutes; Treat the taking-up vaginal speculum that finishes.In the 3rd course of treatment, to treat 3-7 time continuously with second prescription, method is the same.Be after treatment the 3rd course of treatment.
Embodiment 3.
Prepare medicine and treat by following weight proportion:
First prescription: ketoconazole 3g, metronidazole 3g, lactein 5g, Borax (forging) 20g, Cortex Phellodendri 20g, Rhizoma Coptidis 20g, Radix Sophorae Tonkinensis 20g, Borneolum Syntheticum 20g, Herba Menthae 20g porphyrize mix with fluconazol 50ml.Be distributed into 10 bottles.
Second prescription: itraconazole 3g,, metronidazole 3g, lactein 5g, Borax (forging) 20g, Cortex Phellodendri 20g, Rhizoma Coptidis 20g, Radix Sophorae Tonkinensis 20g, Borneolum Syntheticum 20g, Herba Menthae 20g porphyrize mix with fluconazol 50ml.Be distributed into 10 bottles.
Treat 1 time in the 1st, the 2 every days course of treatment, treat continuously 10 times.Patient's emptying bladder is got lithotomy position, and the rearmounted placement of sterilization pudendum vaginal speculum: the NaHCO3 solution 200ml with concentration 4% carries out the vulvovaginal flushing, and vulvovaginal is smeared first prescription medicine then, uses radiation of visible light vulvovaginal 20 minutes; Treat the taking-up vaginal speculum that finishes.In the 3rd course of treatment, to treat 3-7 time continuously with second prescription, method is the same.Be after treatment the 3rd course of treatment.
Claims (4)
1. medicine for the treatment of the recurrent VVC is characterized in that medicine in the raw material is formed and the weight portion proportioning is:
10～30 parts of 2～4 parts of ketoconazoles, 2～4 parts of metronidazoles, 4 parts～6 parts of lactein, 10～30 parts of Borax(calcined), 10～30 parts of Cortex Phellodendris, 10～30 parts of Rhizoma Coptidis, 10～30 parts of Radix Sophorae Tonkinensiss, 10～30 parts of Borneolum Syntheticums and Herba Menthaes, said medicine porphyrize and fluconazol 30～80ml mix.
2. the medicine of treatment recurrent VVC according to claim 1 is characterized in that medicine composition and the weight portion proportioning in the raw material is:
20 parts of 4 parts of ketoconazoles, 2 parts of metronidazoles, 4 parts of lactein, 20 parts of Borax(calcined), 20 parts of Cortex Phellodendris, 20 parts of Rhizoma Coptidis, 20 parts of Radix Sophorae Tonkinensiss, 20 parts of Borneolum Syntheticums and Herba Menthaes, said medicine porphyrize and fluconazol 50ml mix.
3. medicine for the treatment of the recurrent VVC is characterized in that medicine in the raw material is formed and the weight portion proportioning is:
2 parts～4 parts of itraconazoles, 2～4 parts of metronidazoles, 4 parts～6 parts of lactein, 10～30 parts of 10～30 parts of Borax(calcined), 10～30 parts of Cortex Phellodendris, 10～30 parts of Rhizoma Coptidis, 10～30 parts of Radix Sophorae Tonkinensiss, 10～30 parts of Borneolum Syntheticums and Herba Menthaes, said medicine porphyrize and fluconazol 30～80ml mix.
4. the medicine of treatment recurrent VVC according to claim 3 is characterized in that medicine composition and the weight portion proportioning in the raw material is:
20 parts of 2 parts of itraconazoles, 2 parts of metronidazoles, 4 parts of lactein, 20 parts of Borax(calcined), 20 parts of Cortex Phellodendris, 20 parts of Rhizoma Coptidis, 20 parts of Radix Sophorae Tonkinensiss, 20 parts of Borneolum Syntheticums and Herba Menthaes, said medicine porphyrize and fluconazol 50ml mix.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105939963A CN102018805B (en) | 2010-12-17 | 2010-12-17 | Drug for treating relapsable vulvovaginal candidiasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105939963A CN102018805B (en) | 2010-12-17 | 2010-12-17 | Drug for treating relapsable vulvovaginal candidiasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102018805A true CN102018805A (en) | 2011-04-20 |
| CN102018805B CN102018805B (en) | 2011-11-23 |
Family
ID=43860854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105939963A Expired - Fee Related CN102018805B (en) | 2010-12-17 | 2010-12-17 | Drug for treating relapsable vulvovaginal candidiasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102018805B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055493A (en) * | 2015-08-12 | 2015-11-18 | 孟岩 | Medicine for treating gynecological diseases and preparation method and application thereof |
| RU2642666C1 (en) * | 2016-10-13 | 2018-01-25 | Общество с ограниченной ответственностью "Сэлвим" | Method for treatment of recurrent vulvovaginal candidiasis |
-
2010
- 2010-12-17 CN CN2010105939963A patent/CN102018805B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 《中国实用医药》 20070430 周文 乳杆菌在阴道炎防治中的临床作用 第2卷, 第12期 2 * |
| 《中国微生态学杂志》 20070430 吕文英等 女性生殖道感染与阴道菌群失调的关系及治疗 第19卷, 第2期 2 * |
| 《中国社区医师》 20101130 刘玉萍 四联递进联合治疗复发性外阴阴道炎898例疗效观察 第12卷, 第11期 2 * |
| 《甘肃中医》 20100831 裴巧霞 西瓜霜含片配合四联递进疗法治疗外阴阴道假丝酵母菌病所致急性外阴湿疹25例 第23卷, 第8期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055493A (en) * | 2015-08-12 | 2015-11-18 | 孟岩 | Medicine for treating gynecological diseases and preparation method and application thereof |
| RU2642666C1 (en) * | 2016-10-13 | 2018-01-25 | Общество с ограниченной ответственностью "Сэлвим" | Method for treatment of recurrent vulvovaginal candidiasis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102018805B (en) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721131A (en) | Traditional Chinese medicinal suppository for treating female chronic pelvic inflammation and preparation method thereof | |
| CN101744976B (en) | Sterilizing and antipruritic lotion and preparation method thereof | |
| EP2985029A1 (en) | External-use medicament for cleaning and care of the ovaries, vagina and vulva | |
| CN101214357A (en) | Pharmaceutical composition for treating chronic prostatitis | |
| CN102018805B (en) | Drug for treating relapsable vulvovaginal candidiasis | |
| CN101797269A (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN103041247B (en) | Traditional Chinese medicine suppository for curing colpitis and preparation method thereof | |
| CN106822318A (en) | Treat topical agent of senile vahinitis and preparation method thereof | |
| CN103191356B (en) | Antibacterial spray and preparation method thereof | |
| CN101766638B (en) | Local medicament for treating senile vaginitis by replacing estrogen | |
| CN102485239B (en) | Chinese herbal composition used for treating gynecological inflammation | |
| CN103599437B (en) | One treats colpitic traditional Chinese medicine liquid | |
| CN104225036B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating urinary system infection | |
| CN103446277B (en) | Traditional Chinese medicine composition for treating prostatitis by fumigating | |
| CN103861035A (en) | External composition and external medicine/hygiene product for prevention and treatment of gynecological reproductive tract diseases | |
| CN101322771A (en) | Capsules for treating gynecology inflammation | |
| CN1739538A (en) | Suppository for teating mycotic vaginitis | |
| CN104337901A (en) | Chinese medicinal preparation for treating nonspecific cystitis and preparation method thereof | |
| CN103536706B (en) | A kind of Chinese medicine for the treatment of trimester of pregnancy monilial vaginitis smokes lotion | |
| CN102988847A (en) | Medicine composition used for treating vaginitis | |
| CN102670811B (en) | External medicament for treating bacterial vaginosis and colpitis mycotica | |
| CN105168638A (en) | Traditional Chinese medicinal liquid band aid for preventing and treating bedsore complicated with bacterial infection | |
| CN108498687B (en) | Traditional Chinese medicine preparation for pruritus vulvae | |
| CN106138206A (en) | A kind of plant type milch cow special uterus washing liquid and preparation method thereof | |
| CN104784529A (en) | Traditional Chinese medicine composition for fumigation treatment of prostatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111123 Termination date: 20131217 |